【 以下文字转载自 Military 讨论区 】 发信人: lubbock12 (非老非小将), 信区: Military 标 题: 季博士股票大涨是因为干细胞疗法治疗新冠取得了突破 发信站: BBS 未名空间站 (Wed Jan 27 14:53:00 2021, 美东)
这次不再是小白鼠了，是医院里的病人，输入了季博士公司的产品，情况全都迅速好转
Sorrento reported that the first three patients enrolled in its phase 1b study of COVI-MSC were discharged from the hospital within only one week of beginning infusions of the experimental therapy. These patients previously suffered from acute respiratory distress (ARD) or acute respiratory distress syndrome (ARDS) caused by COVID-19.
The company said that one of the patients had been in the hospital for three weeks before receiving COVI-MSC. Another of the patients had been previously discharged but had to be readmitted because of a recurrence of ARD. These patients and a third patient in Sorrento's study improved rapidly after infusions of COVI-MSC.
【 在 lubbock12 (非老非小将) 的大作中提到: 】 : 发信人: lubbock12 (非老非小将), 信区: Military : 标 题: 季博士股票大涨是因为干细胞疗法治疗新冠取得了突破 : 发信站: BBS 未名空间站 (Wed Jan 27 14:53:00 2021, 美东) : 这次不再是小白鼠了，是医院里的病人，输入了季博士公司的产品，情况全都迅速好转 : Sorrento reported that the first three patients enrolled in its phase 1b : study of COVI-MSC were discharged from the hospital within only one week of : beginning infusions of the experimental therapy. These patients previously : suffered from acute respiratory distress (ARD) or acute respiratory distress : syndrome (ARDS) caused by COVID-19. : The company said that one of the patients had been in the hospital for three : ...................
【 以下文字转载自 Military 讨论区 】
发信人: lubbock12 (非老非小将), 信区: Military
标 题: 季博士股票大涨是因为干细胞疗法治疗新冠取得了突破
发信站: BBS 未名空间站 (Wed Jan 27 14:53:00 2021, 美东)
这次不再是小白鼠了，是医院里的病人，输入了季博士公司的产品，情况全都迅速好转
Sorrento reported that the first three patients enrolled in its phase 1b
study of COVI-MSC were discharged from the hospital within only one week of beginning infusions of the experimental therapy. These patients previously
suffered from acute respiratory distress (ARD) or acute respiratory distress syndrome (ARDS) caused by COVID-19.
The company said that one of the patients had been in the hospital for three weeks before receiving COVI-MSC. Another of the patients had been
previously discharged but had to be readmitted because of a recurrence of
ARD. These patients and a third patient in Sorrento's study improved rapidly after infusions of COVI-MSC.
不错啊 ！！
【 在 lubbock12 (非老非小将) 的大作中提到: 】
: 发信人: lubbock12 (非老非小将), 信区: Military
: 标 题: 季博士股票大涨是因为干细胞疗法治疗新冠取得了突破
: 发信站: BBS 未名空间站 (Wed Jan 27 14:53:00 2021, 美东)
: 这次不再是小白鼠了，是医院里的病人，输入了季博士公司的产品，情况全都迅速好转
: Sorrento reported that the first three patients enrolled in its phase 1b
: study of COVI-MSC were discharged from the hospital within only one week
of
: beginning infusions of the experimental therapy. These patients previously
: suffered from acute respiratory distress (ARD) or acute respiratory
distress
: syndrome (ARDS) caused by COVID-19.
: The company said that one of the patients had been in the hospital for
three
: ...................